Project Grant R01HL187901
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $698K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop individualized prediction methods for heart failure progression using digital twins and explainable reinforcement learning. The project will characterize cardiac performance at the individual level using primary echocardiographic images, quantitative echocardiographic measures, and arterial pulse wave velocity...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $165,888 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the genetic architecture of heart failure with preserved ejection fraction (HFPEF) and identify novel therapeutic targets. The recipient will enhance a machine learning model trained to predict HFPEF by incorporating cardiac MRIs and electrocardiograms, improving model specificity for genomic...
- The National Heart, Lung, and Blood Institute awarded The Broad Institute, Inc. $173,825 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct functional genomics research investigating gene regulatory networks in cardiac fibrosis. The award funds research to identify and characterize the transcriptional regulators that promote and maintain the activated cardiac fibroblast cell state in heart failure patients. Cardiac fibrosis—the excessive deposition of...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, operating as Lawrence Berkeley National Laboratory, $2,057,231 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to map and decode the enhancer landscape of human heart development. The award funds a research project that creates a single-cell enhancer atlas of the developing human heart by integrating genome-wide single-cell multiome data from critical...
- The National Heart, Lung, and Blood Institute awarded Duke University $778,772 on August 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolic and contractile dysfunction in heart failure with preserved ejection fraction. The research focuses on understanding the mechanistic link between mitochondrial impairment and loss of muscle strength and power in HFPEF, a systemic disorder affecting 3–4 million U.S. patients predominantly older women. The...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...